Bristol-Myers is suing Synthon to block copies of the drug Zeposia

Bristol-Myers Squibb Co. sued Netherlands-based Synthon BV, alleging that the proposed copies of Zeposia infringed on a patent for the drug, used to treat ulcerative colitis and relapsing forms of multiple sclerosis.

Zeposia’s generic versions of Synthon infringe US Pat. 11,680,050, which covers specific crystalline forms of the drug’s active ingredient, ozanimod hydrochloride, and a method of preparing them, Bristol-Myers and its Receptos LLC unit said in a U.S. complaint filed Tuesday. District Court for the District of Delaware.

Synthon did not immediately respond to a request for comment.

• The patent expires in September 2038, according to the US…